NASDAQ:CVAC - CureVac Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $53.75
  • Forecasted Upside: 186.97 %
  • Number of Analysts: 6
  • Breakdown:
  • 2 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$18.73
▼ -0.68 (-3.50%)

This chart shows the closing price for CVAC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New CureVac Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CVAC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CVAC

Analyst Price Target is $53.75
▲ +186.97% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for CureVac in the last 3 months. The average price target is $53.75, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 186.97% upside from the last price of $18.73.

This chart shows the closing price for CVAC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 6 investment analysts is to hold stock in CureVac. This rating has held steady since October 2020, when it changed from a Sell consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 2 sell ratings
11/28/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 2 sell ratings
2/26/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 2 sell ratings
5/27/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 2 sell ratings
8/25/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 2 sell ratings
11/23/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 3 sell ratings
2/21/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 3 sell ratings
4/22/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 2 sell ratings
5/22/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/22/2022JMP SecuritiesLower Price TargetMarket Outperform$52.00 ➝ $37.00Medium
1/21/2022Bank of AmericaDowngradeNeutral ➝ Underperform$55.00 ➝ $20.00High
1/18/2022JMP SecuritiesInitiated CoverageOutperform$52.00High
12/22/2021UBS GroupDowngradeNeutral ➝ SellHigh
10/22/2021Deutsche Bank AktiengesellschaftInitiated CoverageHold$35.00Medium
7/5/2021Evercore ISIReiterated RatingBuyMedium
7/1/2021Berenberg BankSet Price TargetBuy$123.00High
6/17/2021Bank of AmericaDowngradeBuy ➝ Neutral$50.00High
5/3/2021GuggenheimInitiated CoverageBuyLow
4/26/2021Credit Suisse GroupInitiated CoverageUnderperformMedium
4/26/2021GuggenheimInitiated CoverageBuyHigh
12/10/2020Credit Suisse GroupDowngradeNeutral ➝ Underperform$50.00 ➝ $47.00High
11/17/2020Berenberg BankReiterated RatingBuyLow
9/8/2020Bank of AmericaInitiated CoverageBuy$70.00High
9/8/2020Jefferies Financial GroupInitiated CoverageHold$58.00High
9/8/2020Credit Suisse GroupInitiated CoverageNeutral$68.00High
(Data available from 5/22/2017 forward)

News Sentiment Rating

0.43 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 24 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
10/24/2021
  • 3 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
11/23/2021
  • 1 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
12/23/2021
  • 1 very positive mentions
  • 18 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
1/22/2022
  • 0 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
2/21/2022
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/23/2022
  • 0 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/22/2022
  • 2 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/22/2022

Current Sentiment

  • 2 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
CureVac logo
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidate against COVID-19; CV7202, a prophylactic mRNA-based vaccine, which is in Phase 1 clinical trial for rabies virus glycoprotein; vaccine for lassa yellow fever; vaccine for respirational syncytial virus; CV7301, a second-generation lipid nanoparticle flu vaccine; and vaccines for rota, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CV9202 (BI 1361849), a self-adjuvanting mRNA vaccine that is in Phase 1 clinical trial for non-small cell lung cancer, as well as tumor associated antigens and shared neo-antigens. In addition, it is developing protein-based therapies for Cas9 gene-editing, ocular diseases, and lung respiratory diseases, as well as therapeutic antibodies. The company was founded in 2000 and is headquartered in Tübingen, Germany.
Read More

Today's Range

Now: $18.73
Low: $18.64
High: $20.06

50 Day Range

MA: $17.64
Low: $14.70
High: $19.92

52 Week Range

Now: $18.73
Low: $14.20
High: $125.66

Volume

564,414 shs

Average Volume

590,825 shs

Market Capitalization

$3.50 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.54

Frequently Asked Questions

What sell-side analysts currently cover shares of CureVac?

The following Wall Street analysts have issued research reports on CureVac in the last year: Bank of America Co., Berenberg Bank, Deutsche Bank Aktiengesellschaft, Evercore ISI, JMP Securities, UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for CVAC.

What is the current price target for CureVac?

0 Wall Street analysts have set twelve-month price targets for CureVac in the last year. Their average twelve-month price target is $53.75, suggesting a possible upside of 187.0%.
View the latest price targets for CVAC.

What is the current consensus analyst rating for CureVac?

CureVac currently has 2 sell ratings, 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in CVAC, but not buy more shares or sell existing shares.
View the latest ratings for CVAC.

How do I contact CureVac's investor relations team?

CureVac's physical mailing address is PAUL-EHRLICH-STRABE 15 TUBINGEN, BADEN-WURTTEMBERG 2M, 72076. The company's listed phone number is 49-70-71988-30 and its investor relations email address is [email protected] The official website for CureVac is www.curevac.com. Learn More about contacing CureVac investor relations.